Propanc Biopharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Propanc Biopharma, Inc. (Delaware) on April 1, 2022, covering events occurring on March 29, 2022. The Company, headquartered in Camberwell, Australia, is an emerging growth company with no securities currently registered under Section 12(b) of the Exchange Act.
Key Financial Metrics and Transaction Details
The filing details a financing transaction rather than periodic financial results. Key metrics include:
- Principal Amount: $120,000 convertible promissory note.
- Net Proceeds: $108,000 (after a $12,000 original issue discount).
- Interest Rate: 10% per annum (payable in cash or shares); increases to 24% upon default.
- Maturity Date: March 29, 2023.
- Use of Proceeds: General working capital.
- Conversion Terms: Convertible at 65% of the lowest closing bid price over the prior 10 trading days (55% if a DTC "Chill" is in effect), subject to a 4.99% beneficial ownership limitation.
Material Changes
The Company entered into a Material Definitive Agreement and created a Direct Financial Obligation. This represents a new debt instrument issued to ONE44 Capital LLC. The transaction closed on March 31, 2022. No prior comparable period data is provided in this filing as it is a current event report.
Outlook, Risks, and Unusual Items
Management Commentary: The Company intends to utilize the net proceeds for general working capital purposes.
Risks and Covenants:
- Prepayment Penalties: Significant prepayment premiums apply if the note is paid early (120% within 60 days, 130% within 120 days, 135% within 180 days).
- Asset Disposition Restriction: The Company is restricted from selling substantially all assets without consent, preventing it from becoming a "shell company."
- Default Consequences: Default triggers an interest rate increase to 24% and includes standard events such as insolvency or failure to issue shares upon conversion.
- Regulatory Status: The securities were issued in a private placement under Section 4(a)(2) and Regulation D exemptions.
Investor Verification Checklist
- Verify the current trading status and bid price of Propanc Biopharma common stock on OTC Markets to assess the conversion price.
- Confirm the Company's current cash position to evaluate its ability to service the 10% interest or manage potential prepayment penalties.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) and Convertible Note (Exhibit 4.1) for additional covenants not summarized here.
- Check for any subsequent filings regarding the conversion of the note or acceleration of the maturity date.